The nation of Zimbabwe has declined a substantial US healthcare agreement worth $367m (272 million pounds) over five years because of Washington's insistence on confidential information.
This rejection became public following a official document from December was leaked, which showed President Emmerson Mnangagwa believed the deal was "skewed".
A government spokesperson has since stated that the United States was seeking biological samples for scientific study and commercial purposes while refused to guarantee the benefits from any future medical innovations.
"We will now turn to the difficult and regrettable process of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for continued dialogue to reach a agreement suitable to all parties so the nation's vital HIV treatment initiative can proceed.
Broader Background
This development follows a similar case in Kenya, where a court blocked a similar deal with the US following legal challenges were filed about the security of citizens' medical information.
After returning to office last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump claimed its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to enhance openness and responsibility.
Based on statements, Sixteen African countries have so far agreed to these new agreements, representing more than $18.3bn in new funding.
Details of the Declined Agreement
The money for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration might have yielded extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently on antiretroviral therapy through American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Our nation was requested to provide its biological resources and data over an extended period, without any equivalent guarantee of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"Effectively, our country would provide the basic resources for medical research with no certainty that the final treatments would be available to our citizens if a future pandemic arise."
National Interest and Global Health
He also said that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were disrupting structures already set up through the global organization.
Mangwana cited its Pandemic Benefit-Sharing framework designed to manage potential pandemics.
"This mechanism is intended to guarantee that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the funds to develop them."
The government's concerns regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to continued dialogue with our US partners on how subsequent co-operation could be structured in a manner that respects the independence and dignity of each country."
Health Experts Reaction
A leading public health body said it acknowledged the official position, but urged that negotiations need to persist considering much of the nation's HIV programmes depended on foreign aid.
"Where specific concerns arise, such as those involving data governance or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," the group said.
This impasse emphasises the ongoing tensions between receiving crucial international aid and safeguarding local interests in an increasingly data-driven world.